Jak2 is involved in c-Myc induction by Bcr-Abl

Area of Science:

• Molecular Biology
• Oncology
• Signal Transduction

Background:

• Janus kinase 2 (Jak2) tyrosine kinase is activated in Bcr-Abl positive cells and is implicated in Chronic Myeloid Leukemia (CML).
• c-Myc expression is crucial for the oncogenic effects of Bcr-Abl, with its regulation being a key area of research.

Purpose of the Study:

• To investigate the role of Jak2 in mediating c-Myc protein induction by Bcr-Abl in relevant cellular models.
• To explore the downstream targets of Jak2 in Bcr-Abl positive cells, specifically focusing on c-Myc regulation.

Main Methods:

• Treatment of 32Dp210 Bcr-Abl cells with Jak2-specific inhibitor AG490 and Abl inhibitor STI-571.
• Analysis of c-Myc protein and RNA expression levels following inhibitor treatment.
• Investigation of proteasome-dependent degradation of c-Myc using proteasome inhibitor MG132.
• Assessment of SH2-Bbeta adaptor protein involvement and dominant-negative Jak2 effects on c-Myc and tumor growth.

Main Results:

• Jak2 inhibition by AG490, similar to Abl inhibition by STI-571, suppressed c-Myc protein and RNA induction by Bcr-Abl.
• AG490 treatment inhibited proteasome-dependent degradation of c-Myc protein.
• Expression of a dominant-negative Jak2 mutant reduced c-Myc levels and tumor growth in vivo.
• AG490-induced apoptosis was specific to Jak2 inhibition, as it was not reversed by IL-3.

Conclusions:

• Jak2 activation by Bcr-Abl is essential for the observed increase in c-Myc expression.
• Activated Jak2 influences both c-Myc RNA levels and interferes with its proteasomal degradation.
• Targeting Jak2 represents a potential therapeutic strategy for Bcr-Abl-driven malignancies.